Full Name
Mr Stéphane Marie OUDARD
Job Title
Medical Oncologist
Company
Georges Pompidou Hospital
Speaker Bio
Stéphane Oudard is Professor of Oncology at Georges Pompidou Hospital in Paris, France. He received his medical degree from the Hôtel-Dieu Hospital, University of Paris. Upon completion of his residency in medical oncology in Paris, Professor Oudard obtained his MSc from the Lariboisière-Saint Louis University Hospital, and studied for his doctorate at the Institut Curie. He spent 2 years on a Fellowship in cancer research at Georgetown University, Washington, DC, USA. He was appointed Assistant Professor in Oncology at the Georges Pompidou Hospital, Paris in 2004.
Professor Oudard is currently a member of several French and international international oncology societies, including the French Cancer Society, the European Society for Medical Oncology and the American Society of Clinical Oncology.
He has published more than 450 scientific articles in the fields of urological cancers and translational research, such as angiogenesis, inhibition of glycolysis, and drug resistance. Professor Stéphane Oudard is the author of 25 literature reviews published in international journals. He is active in a number of French, European and international clinical trials (phase I/II/III) as coordinator, investigator and/or co-investigator mainly in GU cancers.
Professor Oudard is currently a member of several French and international international oncology societies, including the French Cancer Society, the European Society for Medical Oncology and the American Society of Clinical Oncology.
He has published more than 450 scientific articles in the fields of urological cancers and translational research, such as angiogenesis, inhibition of glycolysis, and drug resistance. Professor Stéphane Oudard is the author of 25 literature reviews published in international journals. He is active in a number of French, European and international clinical trials (phase I/II/III) as coordinator, investigator and/or co-investigator mainly in GU cancers.
Speaking At